Vitamin B2 Shields Cancer Cells From Death — And Scientists Found How to Reverse It
New research shows riboflavin helps tumors evade ferroptosis. A bacterial compound called roseoflavin may flip that protection off.
Summary
Scientists at the University of Würzburg have discovered that vitamin B2 (riboflavin) — a nutrient essential for human health — also helps cancer cells survive by protecting them from ferroptosis, a natural form of programmed cell death. The study, published in Nature Cell Biology, found that B2 metabolism supports a protein called FSP1, which shields tumor cells from iron-driven oxidative destruction. When researchers limited riboflavin activity in cancer cell models, tumors became far more vulnerable. They then tested roseoflavin, a naturally occurring bacterial compound structurally similar to B2, and found it triggered ferroptosis in cancer cells even at low doses. The findings open a potential new cancer treatment strategy targeting vitamin B2 metabolism, though clinical application is still in early stages.
Detailed Summary
Vitamin B2, also known as riboflavin, is a dietary essential found in dairy, eggs, meat, and leafy greens. It plays well-established roles in energy metabolism and protecting cells from oxidative stress. New research now reveals a troubling flip side: the same protective chemistry that keeps healthy cells alive may also be helping cancer cells evade destruction.
Scientists at the Rudolf Virchow Centre at Julius-Maximilians-Universität Würzburg published findings in Nature Cell Biology showing that riboflavin metabolism actively supports cancer cell survival by reinforcing defenses against ferroptosis. Ferroptosis is a form of programmed cell death driven by iron-dependent oxidative damage to cell membranes. It has emerged as a promising cancer-suppression mechanism, and tumors that resist it are harder to treat.
The research team focused on FSP1, a protein that helps cells avoid unwanted ferroptotic death. Their experiments using genome editing and cancer cell models showed that vitamin B2 supports FSP1 activity. When riboflavin pathways were blocked, cancer cells became significantly more susceptible to ferroptosis — essentially losing a key survival shield.
To translate this insight into a potential therapy, the team tested roseoflavin, a riboflavin-mimicking compound produced naturally by bacteria. In laboratory cancer models, roseoflavin successfully triggered ferroptosis even at low concentrations, validating the concept that disrupting vitamin B2 metabolism could kill tumors.
For health-conscious readers, this research does not suggest avoiding riboflavin-rich foods. B2 remains essential for normal cellular function and cannot be self-synthesized. However, the findings highlight ferroptosis as a meaningful frontier in cancer biology and suggest that precision inhibition of riboflavin pathways — rather than dietary restriction — could become a future therapeutic strategy. Researchers plan to develop more targeted inhibitors for testing in advanced models.
Key Findings
- Vitamin B2 metabolism helps cancer cells resist ferroptosis, a natural tumor-suppressing form of cell death.
- The protein FSP1, supported by riboflavin, acts as a key shield protecting cancer cells from oxidative destruction.
- Blocking riboflavin pathways in lab models made cancer cells significantly more vulnerable to ferroptosis.
- Roseoflavin, a bacterial riboflavin analog, triggered cancer cell death at low concentrations in laboratory experiments.
- Findings published in Nature Cell Biology suggest vitamin B2 metabolism is a viable new cancer therapy target.
Methodology
This is a research summary based on a peer-reviewed study published in Nature Cell Biology, a high-credibility journal. The evidence is derived from in vitro cancer cell models and genome-editing experiments conducted at a research university. No human trials have been conducted; findings are preclinical.
Study Limitations
All experiments were conducted in laboratory cell models, not in animals or humans, limiting direct clinical application. The article does not specify which cancer types were studied, making generalizability unclear. Readers should consult the primary Nature Cell Biology paper for full methodology and statistical details.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.